<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39351798</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>01</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2048-7207</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Oct</Month><Day>01</Day></PubDate></JournalIssue><Title>Journal of the Pediatric Infectious Diseases Society</Title><ISOAbbreviation>J Pediatric Infect Dis Soc</ISOAbbreviation></Journal><ArticleTitle>Safety and Pharmacokinetics of Casirivimab and Imdevimab (CAS+IMD) in Pediatric Outpatients With COVID-19.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">piae105</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1093/jpids/piae105</ELocationID><Abstract><AbstractText>The safety of casirivimab+imdevimab (CAS+IMD) (anti-SARS-CoV-2 monoclonal antibodies [mAbs]) in pediatric outpatients with COVID-19 was evaluated in a randomized, phase 1/2/3 trial. Consistent with adults, CAS+IMD was generally well tolerated with low drug-induced immunogenicity rates. The findings support development of next-generation anti-SARS-CoV-2 mAbs for at-risk pediatric patients.</AbstractText><CopyrightInformation>Â© The Author(s) 2024. Published by Oxford University Press on behalf of The Journal of the Pediatric Infectious Diseases Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Norton</LastName><ForeName>Thomas D</ForeName><Initials>TD</Initials><AffiliationInfo><Affiliation>Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thakur</LastName><ForeName>Mazhar</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ganguly</LastName><ForeName>Samit</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ali</LastName><ForeName>Shazia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chao</LastName><ForeName>Jesse</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Waldron</LastName><ForeName>Alpana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xiao</LastName><ForeName>Jing</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Turner</LastName><ForeName>Kenneth C</ForeName><Initials>KC</Initials><AffiliationInfo><Affiliation>Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davis</LastName><ForeName>John D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Irvin</LastName><ForeName>Susan C</ForeName><Initials>SC</Initials><AffiliationInfo><Affiliation>Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pan</LastName><ForeName>Cynthia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Atmodjo</LastName><ForeName>Dominique</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hooper</LastName><ForeName>Andrea T</ForeName><Initials>AT</Initials><AffiliationInfo><Affiliation>Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hamilton</LastName><ForeName>Jennifer D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hussein</LastName><ForeName>Mohamed</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Subramaniam</LastName><ForeName>Danise</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roque-Guerrero</LastName><ForeName>Lilia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Bio-Medical Research, Miami, Florida, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kohli</LastName><ForeName>Anita</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Arizona Liver Health, Tucson, Arizona, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mylonakis</LastName><ForeName>Eleftherios</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-4624-0777</Identifier><AffiliationInfo><Affiliation>Infectious Diseases Division, Warren Alpert Medical School of Brown University, Providence, Rhode Island, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Houston Methodist Hospital, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Geba</LastName><ForeName>Gregory P</ForeName><Initials>GP</Initials><AffiliationInfo><Affiliation>Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cox</LastName><ForeName>Edward</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Braunstein</LastName><ForeName>Ned</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dakin</LastName><ForeName>Paula</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kowal</LastName><ForeName>Bari</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bhore</LastName><ForeName>Rafia</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DiCioccio</LastName><ForeName>A Thomas</ForeName><Initials>AT</Initials><AffiliationInfo><Affiliation>Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hughes</LastName><ForeName>Diana</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Herman</LastName><ForeName>Gary A</ForeName><Initials>GA</Initials><AffiliationInfo><Affiliation>Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Trial Investigators</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Pediatric Infect Dis Soc</MedlineTA><NlmUniqueID>101586049</NlmUniqueID><ISSNLinking>2048-7193</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">monoclonal antibodies</Keyword><Keyword MajorTopicYN="N">outpatients</Keyword><Keyword MajorTopicYN="N">pediatrics</Keyword><Keyword MajorTopicYN="N">treatment</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>4</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>1</Day><Hour>6</Hour><Minute>55</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>1</Day><Hour>6</Hour><Minute>55</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>1</Day><Hour>5</Hour><Minute>53</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39351798</ArticleId><ArticleId IdType="doi">10.1093/jpids/piae105</ArticleId><ArticleId IdType="pii">7798468</ArticleId></ArticleIdList></PubmedData></PubmedArticle>